Physician profile
Marc James
NPI 1457341836
$8,304.39
in general payments reported to CMS, 2019-2025
22 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $1,259 · 2021: $723 · 2022: $1,365 · 2023: $787 · 2024: $1,043 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,496.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,834.79 | 2019-2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,624.67 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,248.16 | 2022-2025 | Infuse, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $752.15 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $551.95 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $409.72 | 2019-2025 | Precision 1, Total30, Precision7 |
| Notal Vision, INC. | $341.25 | 2019-2025 | Foresee Home |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $327.78 | 2019-2021 | |
| Allergan, INC. | $183.89 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $182.66 | 2019-2021 | |
| Amgen INC. | $169.54 | 2024-2025 | Tepezza |
| Abbvie INC. | $159.05 | 2022-2025 | |
| Oyster Point Pharma, INC. | $103.83 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $91.88 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Dompe US, INC. | $86.87 | 2024-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $82.07 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $34.84 | 2020-2022 | |
| Glaukos Corporation | $32.98 | 2025 | Photrexa Viscous and Photrexa |
| Harrow Eye, LLC | $31.61 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $18.89 | 2019 | |
| Biotissue Holdings INC. | $18.52 | 2022 | |
| Kala Pharmaceuticals, INC. | $17.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.